Which PET tracer shows prostate cancer recurrence better?
NCT ID NCT06604442
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compared two radioactive tracers, piflufolastat (18F) and flotufolastat (18F), used in PET scans to detect prostate cancer that has returned after surgery. The main goal was to see which tracer produces less radioactivity in the bladder, which can interfere with image clarity. The study involved 62 men with low PSA levels (≤0.5 ng/mL) and a history of prostate cancer recurrence after radical prostatectomy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
piflufolastat (18F) and flotufolastat (18F) (radioactive tracers for PET scans)
What this could lead to
If successful, this could help doctors choose the PET tracer that gives clearer images of recurrent prostate cancer, potentially improving detection.
What could go wrong
This is a small, completed Phase 4 study focused on comparing bladder radioactivity, not on patient outcomes. The results may not change clinical practice or directly improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Endeavor Health- Glenbrook Hospital
Glenview, Illinois, 60026, United States
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
Tower Urology
Los Angeles, California, 90048, United States
-
Urology San Antonio
San Antonio, Texas, 78229, United States
-
XCancer Omaha/Urology Cancer Center
Omaha, Nebraska, 68130, United States